Evidence map›Paper›PMID 41128902›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Active immunization with bacteriophage AP205 VLPs results in reduced amyloid load and microgliosis in 5xFAD female mice.

Vladimirs Pilipenko, Ilva Lieknina, Dace Skrastina, Selen Aktas, Beatrise Luize Revina, Jolanta Upite, Baiba Jansone, Kaspars Tars

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vladimirs Pilipenko *Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia. vladimirs.pilipenko@lu.lv.
Ilva Lieknina *Latvian Biomedical Research Center, Riga, Latvia.
Dace SkrastinaLatvian Biomedical Research Center, Riga, Latvia.
Selen AktasDepartment of Molecular Biology and Genetics, Inonu University, Malatya, Turkey.
Beatrise Luize RevinaFaculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia.
Jolanta UpiteFaculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia.
Baiba JansoneFaculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia.
Kaspars TarsLatvian Biomedical Research Center, Riga, Latvia. kaspars.tars@biomed.lu.lv.

Funding

State Research Programme VPP-EM-BIOMEDICĪNA-2022/1-0001
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the leading cause of dementia worldwide and the accumulation of amyloid β (Aβ) oligomers in the brain parenchyma is one of the main characteristics of AD. Pyroglutamate-modified amyloid β (pE

Indexed as

Alzheimer DiseaseAlzheimer VaccinesAmyloid beta-PeptidesBacteriophagesGliosisVaccines, Virus-Like ParticleAnimalsBehavior, AnimalBrainDisease Models, AnimalFemaleMiceMice, TransgenicMicrogliaAlzheimer VaccinesAmyloid beta-PeptidesVaccines, Virus-Like ParticleAlzheimer’s vaccineAnimal behavioral testingPreclinical Alzheimer’s diseaseTransgenic miceVirus-like particles

Identifiers

PMID41128902
PMCPMC12935789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.